Last Price$2.63Cboe Real-Time Last Sale as of 1:05PM ET 1/31/23
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.08(2.94%)
Bid (Size)$2.62 (1,101)
Ask (Size)$2.63 (1,000)
Day Low / High$2.57 - 2.65
Volume1.1 M

Agenus Reports 'Strong Durability' of Combination Drug Candidate Against Sarcoma Based on Expanded Phase 1 Data

12:42PM ET 11/17/2022 MT Newswires
Agenus (AGEN) on Thursday reported that expanded data from a phase 1 study of botensilimab and balstilimab in patients with advanced sarcoma showed that the combination of the two drugs offers "strong durability and superior efficacy," compared with trials for the standard of care and other investigational therapies.

According to the company, data showed that the combination drug had a 46% overall response rate, a 69% disease control rate, and a 12-month overall survival rate of 77%.

Botensilimab was also found to be well-tolerated, with no grade 4 or 5 treatment-related adverse events. Safety profile was found to be similar to what has been previously reported in a phase 1 botensilimab program, the company said.

"We are advancing multiple randomized Phase 2 trials to evaluate the therapeutic potential of this agent across a range of solid tumors," Agenus Chief Medical Officer Steven O'Day said.

Price: 3.22, Change: -0.04, Percent Change: -1.08